Latest News

Knowing what’s on the market for AMD and GA aids in preserving vision.

The pandemic reshapes treatment intervals for neovascular AMD, revealing flexible strategies that maintain visual outcomes and enhance patient care.

The novel system converts light into electrical signals to stimulate retinal cells.

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026.

Advancements in macular laser therapy, emphasizing standardization, precision delivery, and innovative treatment strategies for retinal conditions.

For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice.

The FDA noted in the letter that it is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD.

Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care.

AI revolutionizes ophthalmology with enhanced diagnostics, personalized treatments, and improved surgical precision, offering better patient outcomes and efficient clinical trials.

This approach helps distinguish diseases associated with macular atrophy.

The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe.

Atrophy Advisor aids physicians in personalizing treatment for geographic atrophy in age-related macular degeneration, enhancing patient care and outcomes.

Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease.

Explore the evolving challenges and insights in long-term follow-up for pediatric gene therapy, focusing on data integrity, ethical considerations, and patient retention.

Lock in patient adherence with discussion of study results.

Results showed reduction in geographic atrophy progression and improved visual acuity.

Combining imaging and patient symptoms improves assessment of disease progression.

Ocular Therapeutix accelerates NDA plans for AXPAXLI, targeting wet AMD treatment, following promising phase 3 trial results.

Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions.

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression.

K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.

Gene therapy revolutionizes retinal disease treatment, offering long-lasting solutions and reducing the need for frequent injections in patients with nAMD.

Geographic atrophy management evolves with proactive imaging, personalized therapies, and real-world insights, enhancing patient care and treatment outcomes.

nAMD treatment options may offer positive outcomes to patients by reducing fluid fluctuations associated with poorer outcomes.

Guest lecturer explores the emerging frontiers in ROP therapy and the evolving ethical, clinical, and technological considerations.

Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes.

Choroidal dysfunction plays a crucial role in retinal diseases, highlighting its potential as a therapeutic target and the need for innovative treatments.

Dr. Sharon Fekrat presented a retrospective analysis assessing how antiplatelet and anticoagulant therapy relates to hemorrhage characteristics and outcomes.